

●▶ **AbbVie**

*(FDA, Approval)*

AbbVie's EMBLAVEO (aztreonam and avibactam) received FDA approval for the treatment of adults with complicated intra-abdominal infections

●▶ **Keymed Biosciences Inc**

*(NMPA, Approval)*

NMPA China approved Keymed Biosciences' Stapokibart injections for the treatment of adult patients with seasonal allergic rhinitis

●▶ **Accord Healthcare**

*(EMA, MAA)*

Accord Healthcare's HETRONIFLY (serplulimab) received marketing authorization from the EC for the treatment of extensive-stage small cell lung cancer (ES- SCLC)

●▶ **Moberg Pharma + Alderma**

*(Launch)*

Moberg Pharma + Alderma have announced the launch of Terclara (MOB-015) in Norway



●► **Ariceum Therapeutics**

*(FDA, ODD)*

Ariceum Therapeutics' 225Ac-satoreotide received Orphan Drug Designation from the FDA for the treatment of patients with small cell lung cancer (SCLC)

●► **Bracco Imagine**

*(FDA, FTD)*

BR55 from Bracco Imagine has received FDA Fast Track Designation for the detection of active bowel inflammation in Crohn's disease

●► **Eli Lilly and Company**

*(Clinical Data)*

Eli Lilly announced results from the VIVID-2 extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous Omvoh treatment achieved long-term clinical and endoscopic outcomes

●► **Henlius + Dr. Reddy's**

*(Collaboration)*

Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate in the US and Europe

